Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results from COG0201: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐ Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer’s Disease.
Vijverberg EGB, Catalano S, Hamby ME, Grundman M, Iaci J, Devins T, Caggiano AO. Vijverberg EGB, et al. Among authors: hamby me. Alzheimers Dement. 2025 Jan 9;20(Suppl 6):e089155. doi: 10.1002/alz.089155. eCollection 2024 Dec. Alzheimers Dement. 2025. PMID: 39782655 Free PMC article.
Studying protein interactions in human synapses using array tomography.
Holt K, Taylor LW, McGeachan RI, Simzer E, Colom‐Cadena M, Sánchez‐Aced É, King D, Davies C, Hamby ME, Horrocks MH, Lleo A, Durrant CS, Spires‐Jones TL. Holt K, et al. Among authors: hamby me. Alzheimers Dement. 2025 Jan 9;20(Suppl 8):e094928. doi: 10.1002/alz.094928. eCollection 2024 Dec. Alzheimers Dement. 2025. PMID: 39783436 Free PMC article.
Exploratory CSF proteomics biomarker outcomes of the the phase 2 clinical trial shine to assess the effects of CT1812 in Alzheimer’s patients.
Caro VD, Lizama BN, Cho E, Duong DM, Pandey K, Blennow K, Zetterberg H, Levey AI, Teunissen C, Caggiano AO, Seyfried NT, Hamby ME. Caro VD, et al. Among authors: hamby me. Alzheimers Dement. 2025 Jan 9;20(Suppl 8):e095770. doi: 10.1002/alz.095770. eCollection 2024 Dec. Alzheimers Dement. 2025. PMID: 39783176 Free PMC article.
CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME. Lizama BN, et al. Among authors: hamby me. Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21. Alzheimers Dement. 2024. PMID: 39166791 Free PMC article. Clinical Trial.
An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease.
Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, Di Caro V, Ping L, Blennow K, Zetterberg H, Lah J, Levey AI, Grundman M, Caggiano AO, Seyfried NT, Hamby ME. Lizama BN, et al. Among authors: hamby me. Neurobiol Dis. 2024 Sep;199:106575. doi: 10.1016/j.nbd.2024.106575. Epub 2024 Jun 22. Neurobiol Dis. 2024. PMID: 38914170 Free article. Clinical Trial.
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease.
Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, Tulloch J, Jackson RJ, Catterson JH, Spires-Jones MP, Rose J, Waybright L, Caggiano AO, King D, Gobbo F, Davies C, Hooley M, Dunnett S, Tempelaar R, Meftah S, Tzioras M, Hamby ME, Izzo NJ, Catalano SM, Durrant CS, Smith C, Dando O, Spires-Jones TL. Colom-Cadena M, et al. Among authors: hamby me. Acta Neuropathol. 2024 Feb 6;147(1):32. doi: 10.1007/s00401-023-02679-6. Acta Neuropathol. 2024. PMID: 38319380 Free PMC article.
30 results